Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cornerstone rises on FDA acceptance of hyponatremia drug NDA

This article was originally published in Scrip

Executive Summary

Shares of Cornerstone Therapeutics climbed as high as 9.2% in morning trading on 13 March after it revealed that the US FDA had accepted the new drug application (NDA) for the company's investigational hyponatremia treatment CRTX 080, a highly potent oral non-peptide, which acts on the vasopressin-2 receptor in the kidneys, causing water to be excreted while sparing sodium without affecting other electrolytes.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel